Industry To Meet As MHRA, Dutch Healthcare Inspectorate and PDA Join 30 Industry Leaders Sharing their Views on Innovation in Clinical Trial Supply Practice and Regulations
Posted: 01/05/2011 12:00:00 AM EST
In the wake of a transformed pharmaceutical market due to mergers and acquisitions, industry leaders are to converge in Rotterdam on 27th-28th January 2011, to discuss the latest push in cost cutting and supply stock out mitigation.
Originally initiated in 2007, the official amendments, released by the European Union, come into force on 21 March 2010, in an effort to bring about a more regulated environment for medical devices in Europe not only when gaining CE approval but for safety reporting requirements also.
Pharmaceutical giants such as GlaxoSmithKline, Merck and Boehringer Ingelheim are meeting in January at Pharma IQ's Clinical Trial Supply Europe 2011 Conference to discuss these recent developments and share information on the latest strategies, technology and techniques being employed by leaders of the field to ensure continued process improvement in a recovering financial climate.
In a recent podcast for Pharma IQ, Steve Jacobs President at Global Clinical Supplies Group declared: "Whereas we used to wind up wasting 20-50% of clinical supplies made, the industry is now trying to come up with ways where we can deliver clinical supplies, get the patient in and the study done as fast as possible in a cost reasonable way […]. We all want to know the things we can do to make ourselves more successful. Going to a conference like this is going to allow you to go back to your company a little smarter, with a little bit more experience. […] That is the kind of stuff this conference will be able to give you."
For more information about the upcoming Clinical Trial Supply Europe 2011 Conference visit or http://www.clinicalmedicaldevice.com/ phone + 44 (0) 20 7368 9300.
Media contact: Hinde Liepmannsohn, Marketing Manager, Pharma IQ/IQPC
Ph: 0207 368 9774 or email firstname.lastname@example.org
Top 3 Best Practices for Complying with the Development Safety Update Report (DSUR)
Top 3 Tips for Developing a Globally Applicable Labelling Strategy
7 Predictions for Pharma
Will Clinical Trial Suppliers Move Towards a Solely Virtual Model?
Drug Transporters in ADME
Adopting Single-Use Systems in Biomanufacturing
Freeze-Drying and Optimising Formulation Development for Biologicals
Pharma Bytes: Interview with Per Holm of Lundbeck
Clinical Trials in Egypt and the MENA Region
Functional Foods: Addressing Claims & Labelling Concerns